Home > Research Areas > Cancer > Brain Cancer
Cat. No. Product name CAS No.
DC5113 AEE-788 (NVP-AEE788) Featured

AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2.

497839-62-0
DC11965 Lucanthone

An orally available thioxanthone-based DNA intercalator and inhibitor of the DNA repair enzyme apurinic-apyrimidinic endonuclease 1 (APE1) potential antineoplastic activity, also inhibits autophagy.

479-50-5
DC10617 CBL0137 Featured

CBL0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM.

1197996-80-7
DC10775 CYC065

CYC065 is an orally bioavailable inhibitor of cyclin dependent kinases 2, 5 and 9 (CDK2/5/9) with potential antineoplastic and chemoprotective activities.

1070790-89-4
DC9708 Paxalisib (GDC-0084) Featured

GDC-0084 (RG7666), is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.

1382979-44-3
DC10538 IDH-305 Featured

IDH305 is an inhibitor of the citric acid cycle enzyme isocitrate dehydrogenase [NADP] cytoplasmic (isocitrate dehydrogenase 1; IDH1) with mutations at residue R132 (IDH1(R132)), with potential antineoplastic activity.

1628805-46-8
DC7171 INK-128 Featured

INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms.

1224844-38-5
DC7801 LB-100 Featured

LB-100 is a small-molecular protein phosphatase 2A(PP2A)inhibitor with IC50 of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.

1026680-07-8
DC9707 MK-4101 Featured

MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma.

935273-79-3
DC1056 PD0325901 (PD325901) Featured

PD0325901 (PD325901) is selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM.

391210-10-9
DC2021 Perifosine (KRX-0401) Featured

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM.

157716-52-4
DC10022 PF06840003 Featured

PF-06840003 is an orally available hydroxyamidine and inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1),with potential immunomodulating and antineoplastic activities.

198474-05-4
DC8335 PQR-309(Bimiralisib) Featured

PI3K-IN-2 is a PI3K inhibitor, inhibits pPKB and pS6 with "++++/+++(+)" in A2058 melanoma cell.

1225037-39-7
DC11265 S49076 (hydrochloride) Featured

S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

1265966-31-1
DC10071 S49076 Featured

S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.

1265965-22-7
DC7894 Tandutinib(MLN518)

Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR. Phase 2.

387867-13-2
DC5192 TIC10 isomer

TIC10 isomer(ONC201 isomer) is an isomer of TIC10; TIC10 is a potent, orally active, and stable small molecule that transcriptionally induces TRAIL in a p53-independent manner and crosses the blood-brain barrier.

41276-02-2
Page 1 / Total 1 FirstPrevNextLastGoto